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Anergy Skin Testing and Preventive Therapy for
HIV-Infected Persons: Revised Recommendations
Summary
This report updates and supersedes previous recommendations ( MMWR
1991;40[No. RR–5]:27–33) for the use of anergy skin testing in conjunction with
purified protein derivative (PPD)-tuberculin skin testing of persons infected with
human immunodeficiency virus (HIV). In February 1997, CDC convened a meet-
ing of consultants to discuss current information regarding anergy skin testing,
PPD skin testing, and tuberculosis (TB) preventive therapy for HIV-infected per-
sons. In formulating these recommendations, CDC considered the results of this
meeting, as well as a review of published studies pertaining to PPD and anergy
skin testing of persons who are infected with HIV.
Isoniazid preventive therapy is effective in reducing the incidence of active TB
among persons who have HIV infection and latent TB. Because of the complica-
tions associated with TB disease in HIV-infected persons, these persons must be
screened for tuberculin infection. HIV-infected persons who have positive reac-
tions to skin testing with PPD tuberculin should be evaluated to exclude active
TB and offered preventive therapy with isoniazid if indicated. However, HIV-
infected persons may have compromised ability to react to PPD-tuberculin skin
testing, because HIV infection is associated with an elevated risk for cutaneous
anergy. 
Anergy testing is a diagnostic procedure used to obtain information regard-
ing the competence of the cellular immune system. When a clinician elects
to use anergy testing as part of a multifactorial assessment of a person’s risk for
TB, the two Food and Drug Administration-approved Mantoux-method tests
(mumps and Candida), used together, with cut-off diameters of 5 mm of indura-
tion, are recommended. Efforts to apply the results of anergy testing to pre-
ventive therapy decisions must be supplemented with information concerning
the person’s risk for infection with Mycobacterium tuberculosis. 
Factors limiting the usefulness of anergy skin testing include problems with
standardization and reproducibility, the low risk for TB associated with a diagno-
sis of anergy, and the lack of apparent benefit of preventive therapy for groups
of anergic HIV-infected persons. Therefore, the use of anergy testing in conjunc-
tion with PPD testing is no longer recommended routinely for screening
programs for M. tuberculosis infection conducted among HIV-infected persons
in the United States.
INTRODUCTION
Persons infected with human immunodeficiency virus (HIV) are at risk for having
active tuberculosis (TB) disease (1–3 ) because of either reactivation of latent infection
with Mycobacterium tuberculosis (4 ) or rapid progression of newly acquired infection
(5 ). Active TB, in turn, may hasten the evolution of HIV-related disease, possibly
through mechanisms involving increased cytokine production and accelerated HIV
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replication (6,7 ). Isoniazid preventive therapy administered to persons who have posi-
tive reactions to purified protein derivative (PPD) tuberculin is important in preventing
active TB in the United States. However, HIV-infected persons may have compromised
ability to react to PPD-tuberculin skin testing, because HIV infection is associated with
an elevated risk for cutaneous anergy (8,9 ).
In 1991, CDC published guidelines recommending that anergy skin testing be per-
formed in conjunction with PPD-tuberculin skin testing for HIV-infected persons who
are being evaluated for latent infection with M. tuberculosis (10 ). Demonstration of
anergy in an HIV-infected, PPD-negative person at high risk for infection with M. tuber-
culosis was recommended as an indication for isoniazid preventive therapy. Since the
publication of these guidelines, several studies have been conducted to examine the
results of anergy and PPD skin testing in HIV-infected persons and the effect
of isoniazid for the prevention of TB in anergic HIV-infected persons. In February 1997,
CDC convened a meeting of consultants to discuss these recent publications and other
available data. CDC has used both the results of discussions at this meeting and a
review of published literature to prepare this updated report, which provides recom-
mendations concerning the use of anergy testing for HIV-infected persons in the
United States.
BACKGROUND
Anergy in HIV Disease and Risk for Active TB
in HIV-Infected Persons
Anergy skin testing assesses the responses to skin-test antigens to which a cell-
mediated, delayed-type hypersensitivity (DTH) response is expected. Anergy or DTH
tests placed by using the Mantoux method of intradermal injection have convention-
ally been classified as positive if an induration measuring ≥5 mm is observed at the
injection site within 48–72 hours. Persons who have positive skin tests are considered
to have relatively intact cell-mediated immunity. Persons who do not mount a DTH
response are considered to be anergic and to be at elevated risk for complications of
deficient cell-mediated immunity. PPD-tuberculin skin testing itself elicits a DTH reac-
tion, so persons who have positive PPD responses are not anergic. Responsiveness to
DTH antigens may be decreased in HIV-infected persons, and the 1991 guidelines (10 )
recommended the use of companion or “control” antigens in conjunction with PPD
testing to provide additional information about a person’s ability to mount a DTH
response.
Impaired DTH response, which is directly related to decreasing CD4+ T-lymphocyte
count, is a predictive factor for progression of acquired immunodeficiency syndrome
and mortality in HIV-infected persons (11–14 ). In some studies, after the data were
stratified by CD4+ count, anergy skin-test results have provided additional prognostic
information about HIV-related complications and death (11–14 ). The results of several
studies have suggested that HIV-infected persons diagnosed as anergic have a greater
risk for active TB than do nonanergic, PPD-negative, HIV-infected persons from the
same population (15–19 ). In addition, among HIV-infected persons who have positive
PPD-tuberculin skin-test results, data from one study demonstrated that those who
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did not respond to testing with a control antigen had a higher risk for active TB than
did PPD-positive persons who reacted to such testing (19 ). Although CD4+ counts in
HIV-infected persons have been reported as inversely related to their risk for active TB,
being anergic has in itself been associated with an elevated risk for TB, even after the
data were stratified by CD4+ count (16,19 ). Two studies suggest that mortality may be
increased in HIV-infected persons who have active TB and who do not respond to
testing with PPD compared with patients who have TB and HIV infection from the
same population who respond to PPD testing (20,21 ).
Anergy and Interpretation of PPD-Tuberculin Skin Tests
The results from supplemental anergy testing, in conjunction with PPD-tuberculin
skin testing, have been interpreted in two ways (10 ). A positive DTH response
to anergy testing, in conjunction with a negative PPD skin-test result, has been inter-
preted as evidence that the negative PPD test result is a true negative and the person
tested is not infected with M. tuberculosis. Lack of DTH response to anergy skin test-
ing, in conjunction with a negative PPD skin-test result, has been interpreted as
evidence that the person is unable to mount a positive response to PPD even if in-
fected with M. tuberculosis.
Certain issues, however, compromise the validity of both of these interpretations.
Selective nonreactivity to PPD is a recognized phenomenon in some patients with ac-
tive culture-positive TB (22,23 ). The observations that mumps reactivity may remain
after loss of PPD reactivity (24 ) and that PPD boosting can occur in persons who have
an initial positive reaction to control antigens (25–27 ) suggest the possibility that DTH
response to other antigens may be preserved after loss of PPD reactivity. Therefore, a
DTH response is not proof that a negative PPD applied at the same time indicates
absence of infection with M. tuberculosis. Lack of response to one or more control
antigens, however, does not always mean inability to respond to PPD. In populations
in which the prevalence of tuberculin reactivity is high, the percentage of persons who
react to PPD may be higher than the percentage reacting to several other antigens
(28,29 ). Even in populations in which the prevalence of PPD positivity is low, some
persons respond to PPD testing despite lack of response to a companion antigen (19 ).
Furthermore, a valid demonstration of anergy does not predict infection with M. tuber-
culosis; instead, it indicates that, for the anergic person, the PPD test results may not
be useful in judging the likelihood of infection with M. tuberculosis and the need for
TB preventive therapy.
ANERGY SKIN TESTING AND DECISIONS REGARDING TB
PREVENTIVE THERAPY
Because of the complications associated with active TB in HIV-infected persons,
these persons must be screened for latent TB infection and receive complete preven-
tive treatment with isoniazid if indicated. Several factors limit the usefulness of anergy
skin testing for making decisions regarding TB preventive therapy for HIV-infected
persons in the United States. These factors include problems with the standardization
and reproducibility of anergy skin-testing methods, the variable risk for TB associated
with a diagnosis of anergy, and the lack of documented benefit of anergy skin testing
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as part of screening programs for M. tuberculosis infection among HIV-infected
persons.
Difficulties in Interpreting Anergy Skin-Testing Results
The decision of whether to perform anergy testing cannot be separated from deter-
mining how to perform it. Lack of standardization and lack of outcome data based on
uniform antigens and tests are among the greatest obstacles to evaluating the effec-
tiveness of anergy testing and making decisions concerning TB preventive therapy.
Studies have been based on a variety of control antigen preparations and skin-test
administration and methods for reading test results. Studies involving multiple-DTH
antigen panels have demonstrated that several antigens may be necessary to maxi-
mize the likelihood that all persons able to respond are identified (29,30 ). DTH
responses may vary in different populations of immunocompetent groups (31 ). DTH
reactions of <5 mm of induration have been reported in young children (32 ), who
might not be expected to have fully developed cellular immunity, and reactions of
<5 mm of induration also have been noted in response to diluent without antigen
(33–35 ).
The variability in test readings noted for the PPD-tuberculin skin test (36,37 ) is
likely to be associated with other DTH tests. Data from one study of variation between
duplicate PPD tests (37 ), indicated that more than half of the discordant readings
occurred in persons with one test measured as zero and the other as 1–4 mm of indu-
ration. Serial anergy testing among HIV-infected persons has shown unpredictable
differences over time (24,38 ). This variation may result from changes in host immune
competence or from characteristics of the tests themselves. Furthermore, the choice
and number of companion antigens and the criteria used for the interpretation of re-
sults of anergy testing may lead to false classification of a) persons with intact
cell-mediated immunity as anergic or b) anergic persons as nonanergic.
The applicability of skin-testing methods to pediatric populations is uncertain. Chil-
dren who have HIV infection have had DTH responses, and lack of response has been
associated with the stage of HIV-related disease (39,40). However, no clear utility of
anergy testing for the evaluation for TB among children has been established (41 ).
Skin testing for DTH reactions is an important tool in diagnosing a variety of primary
immunodeficiency diseases (i.e., non-HIV–related immunodeficiency diseases). There-
fore, any recommendations regarding anergy testing should take into account its
value in patients who have primary immunodeficiency diseases.
Anergy and Risk for Active TB
In studies conducted both in the United States and elsewhere, no definite associa-
tion has been determined between anergy and the risk for active TB in HIV-infected
persons; the results of these studies indicated that the magnitude of the risk is variable
and the reason for the variation uncertain. Rates of TB in groups defined as anergic
have ranged from zero to >12 per 100 person-years. The risk for active TB in anergic
HIV-infected persons may be associated with ongoing risk for M. tuberculosis trans-
mission (i.e., residence in areas of high TB case rates), rather than with a high
probability of latent M. tuberculosis infection alone (15–19,42–45 ). This finding im-
plies that any effect of isoniazid preventive therapy might be attributable not only to
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prevention of reactivation of latent infection, but also (or instead) to primary prophy-
laxis against new acquisition of infection.
Effect of TB Preventive Therapy in Anergic Persons
Two recent studies of 6 months of isoniazid preventive therapy among anergic
persons at risk for infection with M. tuberculosis have been conducted. One study
involving HIV-positive anergic patients in the United States demonstrated no statisti-
cally significant effect of therapy, despite a 56% reduction in rates of TB from 0.9 per
100 person-years in placebo recipients to 0.4 per 100 person-years in isoniazid recipi-
ents (42 ). The failure to find statistical significance with a 56% point estimate for
protection may result from a lower-than-expected TB case rate in placebo recipients.
Researchers concluded that, because the TB rate in the untreated group was low
(0.9%), preventive therapy would have minimal impact in reducing the number of in-
cident TB cases among HIV-positive anergic persons but would result in a substantial
number of uninfected persons being treated with isoniazid. The other study, involving
HIV-positive anergic patients in Kampala, Uganda, demonstrated a high TB case rate
(three per 100 person-years) in placebo recipients, but only a statistically insignificant
(17%) reduction in isoniazid recipients (43 ). In summary, even if anergic HIV-infected
persons are assumed to be at high risk for active TB and are administered isoniazid
preventive therapy, the effectiveness of this intervention has not been established for
this population.
METHODS AND USES FOR ANERGY SKIN TESTING
Mumps and Candida antigens have been approved by the Food and Drug Admini-
stration (FDA) for intradermal DTH testing to assess cell-mediated immunity. Mumps
skin-test antigen has been available for a longer time; lack of response to mumps an-
tigen in HIV-infected persons has been associated with risk for TB (19 ), but some
patients who have lost PPD reactivity with progression of HIV disease may still react
to mumps (24 ). Candida DTH skin-test antigen was approved more recently. Data link-
ing DTH response to this Candida antigen and risk for TB are limited, and published
studies describing Candida skin-test responses have used different products marketed
as allergenic extracts.
Both mumps and Candida antigens are applied by using the Mantoux method. The
number of control antigens and the method of reading may affect the usefulness of
Mantoux-method skin tests. More than two control antigens may be needed to avoid
misclassifying immunocompetent persons as anergic (29,30 ). Limited information is
available regarding the sensitivity and specificity of the two FDA-approved DTH tests
used together. Other antigens (e.g., fluid tetanus toxoid and Candida extracts mar-
keted for allergy testing) frequently are used for anergy testing, but with differing
preparations, dosages, and dilutions.
The conventional cut-off measurement of induration diameter for interpreting
a Mantoux-method skin-test result as positive is 5 mm of induration. In recent years,
attempts have been made to detect DTH in HIV-infected patients by using smaller
cut-off diameters (3 mm, 2 mm, 1 mm, or “any induration”). In addition to the valid-
ity concerns already noted, the use of smaller cut-offs is subject to technical
Vol. 46 / No. RR-15 MMWR 5
difficulties (46 ) and has not improved predictive value. A multiple-puncture test bat-
tery (MULTITEST CMI®), which includes seven antigens and a diluent control, has
been approved by the FDA for DTH testing. Results have been associated with clinical
outcomes in several studies of HIV-infected persons (12,15–17 ). The use of this prod-
uct, however, is likely to be limited by cost and availability.
Because several studies suggest a relationship between anergy and risk for TB,
health-care providers may find the results of anergy testing useful in individual situ-
ations, despite the lack of consensus on how to perform anergy skin testing. Efforts to
apply the results of anergy testing to evaluation of latent TB infection and preventive
therapy decisions should be supplemented by information concerning the person’s
risk for exposure to and infection with M. tuberculosis. Used in this way, anergy tests,
in conjunction with PPD testing, may assist in estimating TB risk for selected HIV-
infected patients in specific situations. If a decision is made to perform anergy testing,
technical expertise, feasibility, and cost may be important factors in choosing which
test(s) to employ. The purpose of anergy testing also may be a factor: if the primary
concern is to avoid misclassifying anergic persons as nonanergic, the use of two
Mantoux-method tests with a 5-mm of induration cut-off may be appropriate. Use of
more antigens may be indicated, however, if the primary concern is to avoid misclas-
sifying immunocompetent persons as anergic. The expertise of the health-care
provider and a clear understanding of the limitations of anergy testing are critical to
appropriate use.
ROLE OF ANERGY SKIN TESTING IN TB PREVENTION
AND CONTROL PROGRAMS
Isoniazid preventive therapy administered to HIV-positive persons who have posi-
tive reactions to PPD tuberculin is important both as a personal health intervention
and as part of efforts to prevent active TB disease in the United States. The prevalence
of M. tuberculosis infection and active TB disease differs among different groups of
the U.S. population infected with HIV. To reach a community’s groups at high risk for
TB, CDC has recommended that the design of tuberculin screening programs be
based on local data regarding the prevalence and incidence of M. tuberculosis infec-
tion and the sociodemographic characteristics of patients with TB and M. tuberculosis
infection (47 ).
In studies conducted in the United States in which preventive therapy was admin-
istered principally to PPD-positive persons (44,45 ), no cases of TB were observed in
anergic persons. (In one of these reports, selected anergic persons also received
isoniazid [45 ].) In a multicenter study (19 ), the effect of area of residence on risk for
TB was much greater than that of anergy. The precise risk for TB in HIV-positive aner-
gic persons in the United States cannot be determined; however, the overall risk
seems to be low. In addition, there are no simple skin-testing protocols that can reli-
ably identify persons as either anergic or nonanergic and that have been proven to be
feasible for application in public health tuberculosis screening programs. In the United
States, the public health impact of finding and treating patients who have infectious
TB to prevent further transmission and of providing preventive therapy to PPD-
positive, HIV-infected persons to prevent additional infectious TB cases should be
greater than the effect of preventive therapy for HIV-positive anergic persons.
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RECOMMENDATIONS
Programmatic Use of Anergy Testing
Since the publication of guidelines in 1991, additional information has documented
limitations in the usefulness of anergy testing in public health tuberculosis screening
programs. These limiting factors include the variability in the available anergy testing
methods, their lack of reproducibility, the variation in absolute risk for TB among dif-
ferent anergic groups, and the lack of demonstrated efficacy of a preventive therapy
program in anergic HIV-infected groups. Therefore, anergy testing in conjunction with
PPD-tuberculin testing is no longer routinely recommended for inclusion in screening
programs for M. tuberculosis infection among HIV-infected persons. However, DTH
evaluation may assist in guiding individual decisions regarding preventive therapy in
selected situations.
TB Preventive Therapy Among HIV-Positive, PPD-Positive
Persons
Unless specifically contraindicated, HIV-positive persons a) who have positive reac-
tions to PPD tuberculin (≥5 mm of induration), b) who have not already been treated
for TB infection, and c) whose test results exclude active TB should be considered for
12 months of preventive therapy with isoniazid (48 ). This preventive therapy is indi-
cated even if the date of PPD skin-test conversion cannot be determined.
TB Preventive Therapy Among HIV-Positive, PPD-Negative
Persons
When assessing HIV-infected persons who have negative PPD-tuberculin skin-test
results or who are known to be anergic, the most important factors in considering TB
preventive therapy are the likelihood of exposure to transmissible active TB and the
likelihood of latent M. tuberculosis infection. Preventive therapy should be considered
for HIV-infected persons who do not have a documented positive PPD-tuberculin re-
sponse but who have had recent contact with patients who have infectious pulmonary
TB. Repeat PPD testing of initially PPD-negative contacts 3 months after cessation
of contact with infectious TB is sometimes used to assist in decisions about duration
of preventive therapy (49 ). However, most of these patients should complete a full
12-month course of isoniazid preventive therapy.
In certain cases, preventive therapy with isoniazid for persons who are not PPD
positive also may be considered. Such therapy may be beneficial for a) children who
are born to HIV-infected women and are close contacts of a person who has infectious
TB and b) HIV-infected adults who reside or work in institutions and are continually
and unavoidably exposed to patients who have infectious TB. Some experts recom-
mend continuing isoniazid preventive therapy indefinitely for HIV-infected persons
who have an ongoing high risk for exposure to M. tuberculosis (e.g., inmates of pris-
ons in which the prevalence of TB is high). In these situations, the results of anergy
testing may be useful for deciding which persons should be offered prolonged pre-
ventive therapy in settings in which a) exposure is likely but PPD conversion has not
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occurred, b) the consideration of primary prophylaxis may arise, and c) the most vul-
nerable persons in immunologic terms may have high priority for preventive therapy.
Future Programmatic Directions
For formulating future recommendations regarding programmatic uses of anergy
testing, results from systematic studies of the two FDA-approved Mantoux-method
tests used together with a cut-off diameter of 5-mm of induration would be useful,
as would comparisons between results with this combination and with the seven-
antigen multipuncture battery. Ultimately, development of a simpler standard skin test
or of another method for measuring the same components of immune responses
more reliably is desirable.
CONCLUSIONS
Recent studies suggest that impaired DTH is related to risk for active TB in some
HIV-infected populations, despite variability in anergy skin-testing procedures. When
a clinician elects to use anergy testing as part of a multifactorial assessment of a per-
son’s risk for TB, the two FDA-approved Mantoux-method tests (mumps and
Candida ), used together and with cut-off diameters of 5 mm of induration, are recom-
mended. Studies based on these approaches may result in data useful for formulating
guidelines regarding future programmatic uses of anergy testing. Improvements in TB
screening and preventive therapy practices in HIV-infected persons require better
standardization of anergy testing methods and validation of their predictive value or
development of an adequate alternative measure of cellular immunity or of an alterna-
tive test for the detection of latent TB infection.
In selected situations, anergy testing may assist in guiding individual decisions re-
garding individual therapy. However, results of currently available anergy-testing
methods in U.S. populations have not been demonstrated to make a useful contribu-
tion to most decisions about isoniazid preventive therapy. Therefore, anergy testing is
no longer recommended as a routine component of TB screening among HIV-infected
persons in the United States.
References
1. Castro KG. Tuberculosis as an opportunistic disease in persons infected with human immu-
nodeficiency virus. Clin Infect Dis 1995;21(suppl. 1):S66–S71.
2. Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with human
immunodeficiency virus infection. N Engl J Med 1991;324:1644–50.
3. Gutman LT, Moye J, Zimmer B, Tian C. Tuberculosis in human immunodeficiency virus-
exposed or -infected United States children. Pediatr Infect Dis 1994;13:963–8.
4. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among
intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;
320:545–50.
5. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated pro-
gression among persons infected with the human immunodeficiency virus. N Engl J Med
1992;326:231–5.
6. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence
of active tuberculosis and progression of HIV infection. Lancet 1993;342:268–72.
7. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis  on HIV rep-
lication: role of immune activation. J Immunol 1996;157:1271–8.
8 MMWR September 5, 1997
8. Graham NMH, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivity and skin test
anergy in HIV-1 seropositive and -seronegative intravenous drug users. JAMA 1992;267:
369–73.
9. Markowitz N, Hansen NI, Wilcosky TC, et al. Tuberculin and anergy testing in HIV-seropositive
and HIV-seronegative persons. Ann Intern Med 1993;119:185–93.
10. CDC. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for
anergy testing and management of anergic persons at risk of tuberculosis. MMWR 1991;40
(No. RR-5):27–33.
11. Birx DL, Brundage J, Larson K, et al. The prognostic utility of delayed-type hypersensitivity
skin testing in the evaluation of HIV-infected patients. J Acquir Immune Defic Syndr 1993;
6:1248–57.
12. Gordin FM, Hartigan PM, Klimas NG, et al. Delayed-type hypersensitivity skin tests are an
independent predictor of human immunodeficiency virus disease progression. J Infect Dis
1994;169:893–7.
13. Blatt SP, Hendrix CW, Butzin CA, et al. Delayed-type hypersensitivity skin testing predicts pro-
gression to AIDS in HIV-infected patients. Ann Intern Med 1993;119:177–84.
14. Dolan MJ, Clerici M, Blatt SP, et al. In vitro T cell function, delayed-type hypersensitivity skin
testing, and CD4+ T cell subset phenotyping independently predict survival time in patients
infected with human immunodeficiency virus. J Infect Dis 1995;172:79–87.
15. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active
tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992;268:504–9.
16. Antonucci G, Girardi E, Raviglione MC, et al. Risk factors for tuberculosis in HIV-infected per-
sons. JAMA 1995;274:143–8.
17. Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among
HIV-infected patients. AIDS 1993;7:1345–9.
18. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic
patients infected with HIV. Ann Intern Med 1993;119:194–8.
19. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States
among HIV-infected persons. Ann Intern Med 1997;126:123–32.
20. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on
mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop
Med Hyg 1995;89:78–82.
21. Whalen C, Okwera A, Johnson J, et al. Predictors of survival in human immunodeficiency
virus-infected patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1996;153:
1977–81.
22. Nash DR, Douglass JE. Anergy in active pulmonary tuberculosis. Chest 1980;77:32–7.
23. Rooney JJ, Crocco JA, Kramer S, Lyons HA. Further observations on tuberculin reactions in
active tuberculosis. Am J Med 1976;60:517–22.
24. Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in persons with
HIV infection. Am J Respir Crit Care Med 1996;153:1982–4.
25. Webster CT, Gordin FM, Matts JP, et al. Two-stage tuberculin skin testing in individuals with
human immunodeficiency virus infection. Am J Respir Crit Care Med 1995;151:805–8.
26. Huebner RE, Schein MF, Hall CA, Barnes SA. Delayed-type hypersensitivity anergy in human
immunodeficiency virus-infected persons screened for infection with Mycobacterium tuber-
culosis. Clin Infect Dis 1994;19:26–32.
27. Hecker MT, Johnson JL, Whalen CC, Nyole S, Mugerwa RD, Ellner JJ. Two-step tuberculin
testing in HIV-infected persons in Uganda. Am J Respir Crit Care Med 1997;155:81–6.
28. Shaheen SO, Aaby P, Hall AJ, et al. Cell mediated immunity after measles in Guinea-Bissau:
historical cohort study. Br Med J 1996;313:969–74.
29. Miller WC, Thielman NM, Swai N, et al. Delayed-type hypersensitivity testing in Tanzanian
adults with HIV infection. J Acquir Immune Defic Syndr 1996;12:303–8.
30. Wright PW, Crutcher JE, Holiday DB. Selection of skin test antigens to evaluate PPD anergy.
J Fam Pract 1995;41:59–64.
31. Hickie C, Hickie I, Silove D, Wakefield D, Lloyd A. Delayed-type hypersensitivity skin testing:
normal values in the Australian population. Int J Immunopharmacol 1995;17:629–34.
32. Munoz AI, Limbert D. Skin reactivity to Candida and streptokinase-streptodornase antigens
in normal pediatric subjects: influence of age and acute illness. J Pediatr 1977;91:565–8.
Vol. 46 / No. RR-15 MMWR 9
33. Kniker WT, Anderson CT, Roumiantzeff M. The multi-test system: a standardized approach
to evaluation of delayed hypersensitivity and cell-mediated immunity. Ann Allergy 1979;43:
73–9.
34. Edwards LB, Comstock GW, Palmer CE. Contributions of northern populations to the under-
standing of tuberculin sensitivity. Arch Environ Health 1968;17:507–16.
35. León ME, Ward B, Kanashiro R, et al. Immunologic parameters 2 years after high-titer measles
immunization in Peruvian children. J Infect Dis 1993;168:1097–104.
36. Bearman JE, Kleinman H, Glyer VV, LaCroix OM. A study of variability in tuberculin test reading.
Am Rev Respir Dis 1964;90:913–9.
37. Chaparas SD, Vandiviere HM, Melvin I, Koch G, Becker C. Tuberculin test: variability with the
Mantoux procedure. Am Rev Respir Dis 1985;132:175–7.
38. Caiaffa WT, Graham NMH, Galai N, Rizzo RT, Nelson KE, Vlahov D. Instability of delayed-type
hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med
1995;155:2111–7.
39. Blanche S, Le Deist F, Fischer A, et al. Longitudinal study of 18 children with perinatal LAV/HTLV
III infection: attempt at prognostic evaluation. J Pediatr 1986;109:965–70.
40. Raszka WV Jr, Moriarty RA, Ottolini MG, et al. Delayed-type hypersensitivity skin testing in
human immunodeficiency virus-infected pediatric patients. J Pediatr 1996;129:245–50.
41. Nachman SA, Navaie-Waliser M. Tuberculin skin testing in a pediatric population exposed
to human immunodeficiency virus. Pediatr Infect Dis J 1996;15:1941–2.
42. Gordin FM, Matts J, Miller C, et al. A controlled trial of isoniazid in persons with anergy and
human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med
1997;337:315–20.
43. Whalen C, Okwera A, Johnson J, et al. Preventive therapy for tuberculosis in HIV-infected
Ugandans. N Engl J Med (in press).
44. Daley CL, Hahn JA, Hopewell PC, Moss AR, Schechter GF. Incidence of tuberculosis in injection
drug users in San Francisco, 1990–1994 [Abstract no. 11]. Lancet Conference on the Challenge
of Tuberculosis, Washington, September 1995.
45. Graham NMH, Galai N, Nelson KE, et al. Effect of isoniazid chemoprophylaxis on HIV-related
mycobacterial disease. Arch Intern Med 1996;156:889–94.
46. Huebner RE, Villarino ME, Snider DE Jr. Tuberculin skin testing and the HIV epidemic.
JAMA 1992;267:409–10.
47. CDC. Essential components of a tuberculosis prevention and control program: recommen-
dations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1995;44
(No. RR–11):1–16.
48. Treatment of tuberculosis and tuberculosis infection in adults and children [Editorial]. Am J
Respir Crit Care Med 1994;149:1359–74.
49. CDC. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons
infected with human immunodeficiency virus. MMWR 1997;46(No. RR–12).
10 MMWR September 5, 1997
Vol. 46 / No. RR-15 MMWR 11
12 MMWR September 5, 1997
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control
and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis
for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to
listserv@listserv.cdc.gov. The body content should read SUBscribe mmwr-toc. Electronic copy also is
available from CDC’s World-Wide Web server at http://www.cdc.gov/ or from CDC’s file transfer protocol
server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government
Printing Office, Washington, DC 20402; telephone (202) 512-1800.
Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments.
The reporting week concludes at close of business on Friday; compiled data on a national basis are officially
released to the public on the following Friday. Address inquiries about the MMWR Series, including material
to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta,
GA 30333; telephone (404) 332-4555.
All material in the MMWR Series is in the public domain and may be used and reprinted without
permission; citation as to source, however, is appreciated.
✩U.S. Government Printing Office: 1997-532-228/67022 Region IV
MMWR
